From our region’s epicenter of discovery, Greater Philadelphia researchers and companies are part of the global race to get a handle on COVID-19, including Biomeme, The Wistar Institute, and the newly formed Penn Center for Research on Coronaviruses and Other Emerging Pathogens (PENNCoV).
Article from The Philadelphia Citizen
The future of research and development, in rare diseases and beyond, is Philadelphia.
By moving its R&D team to University City this year, publically traded gene therapy company Amicus Therapeutics now calls the Greater Philadelphia region’s bustling cell and gene therapy ecosystem home.
Article from the Philadelphia Inquirer
The biotech company Immunocore, with its U.S. headquarters in Montgomery County, announced a $130 million Series B financing round to continue the development of T-cell receptor therapies.
Article from the Philadelphia Business Journal
Penn Medicine spinout Passage Bio raised $216 million through an initial public offering to support the continued development of clinical trials for gene therapies to treat rare central nervous system disorders – exceeding expectations and proving that cell and gene therapies can thrive in the Greater Philadelphia region.
Article from the Philadelphia Business Journal
“This is not a bubble, it’s Philadelphia’s moment,” Steven Nichtberger, CEO of Cabaletta Bio offers his perspective on the region’s exponential growth as the epicenter of cell and gene therapy.
Article from the Philadelphia Inquirer
PACT Philadelphia’s annual report ranks the region seventh in the country for VC funding after a record-setting $2.5 billion invested in 2019, fueled by a steady stream of life sciences deals and activity among cell and gene therapy and connected health companies.
Report from PACT
Last year, three cancer patients were treated with their own CRISPR-edited T cells as part of a groundbreaking U.S. trial to determine the safety of such a treatment.
The result? A promising breakthrough for gene editing.
Article from Wired
See inside the new Spring House Innovation Park, a soon-to-be hub of life sciences innovation housing companies like Anpac Bio – which will open its U.S. HQ and very first east coast clinical lab site on the campus.
Article from Philadelphia magazine
Another life sciences IPO for Greater Philadelphia: Gene therapy startup Passage Bio plans to go public via a $125 million IPO, to continue developing six gene therapy candidates for central nervous system diseases, including dementia.
Article from the Philadelphia Business Journal
New York-based Deerfield Management and King of Prussia’s The Discovery Labs will open the Center for Breakthrough Medicines, occupying 680,000 square feet of The Discovery Labs space to provide pre-clinical through commercial manufacturing of cell and gene therapies, adding to our rich ecosystem as a cell and gene therapy hub.
Article from Technical.ly
Select Greater Philadelphia (Select) is the business attraction organization for northern Delaware, southern New Jersey, and southeastern Pennsylvania. A non-profit entity, Select highlights Greater Philadelphia’s unique business assets to national and global audiences with the ultimate goal of growing the economic vibrancy of our collective community through attracting new businesses and new jobs to our 11-county region. Select assists companies interested in locating in Greater Philadelphia by providing resources, detailed information, and connections.
200 South Broad Street, Suite 700
Philadelphia, PA 19102 - 3789